Psoriasis News and Research

Latest Psoriasis News and Research

Idera second quarter net loss increases to $6.3 million

Idera Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2011. Idera is a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-Like receptors (TLRs).

5 Aug 2011

Stress management can improve chronic skin conditions

As anyone with a chronic, inflammatory skin condition, such as psoriasis, rosacea or acne, knows, dealing with unpredictable flares can cause considerable stress and have a negative impact on a person's overall well-being.

4 Aug 2011

British scientists find seven new gene variants linked to prostate cancer

Cancer Research UK-funded scientists have taken a further step to identifying men at a greater risk of prostate cancer with the discovery of seven new variants in the human genome that increase the chances of developing the disease. The research is published in Nature Genetics.

3 Aug 2011

Can-Fite commences CF101 phase 2/3 trial for treatment of Psoriasis

Can-Fite BioPharma Ltd, a biotechnology company developing small molecule drugs for the treatment of inflammatory, ophthalmic, and liver diseases, traded on the Tel Aviv Stock Exchange announced today that it has commenced patient enrolment in a phase 2/3 clinical trial of CF101 for the treatment of Psoriasis.

2 Aug 2011

Humira defect lawyers file lawsuit against Abbott in Texas state court

Humira defect lawyers filed a lawsuit against Abbott Laboratories in Texas state court claiming Abbott's blockbuster drug, Humira, caused a life-threatening disease, leukemia.

30 Jul 2011

AARDA develops a plan to calculate one's own Autoimmune Quotient

Hollywood bombshell Kim Kardashian recently shared her diagnosis of the autoimmune disease psoriasis on her E! reality TV series, "Keeping Up With The Kardashians."

29 Jul 2011

Celgene reports second quarter total revenue of $1.18 billion

Celgene Corporation announced non-GAAP net income of $417 million, or non-GAAP diluted earnings per share of $0.89, for the quarter ended June 30, 2011. Non-GAAP net income for the second quarter of 2010 was $323 million, or non-GAAP diluted earnings per share of $0.69.

28 Jul 2011

Male sex hormones can protect men from inflammatory diseases

It's all down to the testosterone: men are usually more muscular than women, they have deeper voices and more body hair. And - men are less susceptible to inflammatory diseases and allergies than women. This is also due to the male sex hormones as pharmacists at the Friedrich Schiller University Jena have shown in a recent study.

27 Jul 2011

When psoriasis strikes the famously beautiful

It appears that psoriasis spares none. Reality TV star Kim Kardashian has been reportedly diagnosed with the skin condition. Her condition was revealed on a recent episode of “Keeping Up with the Kardashians” on E!.

25 Jul 2011

Janssen receives FDA Complete Response letter for SIMPONI sBLA to treat RA

Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response letter for its supplemental Biologics License Application (sBLA) for SIMPONI.

25 Jul 2011

Impaired immunological memory causes psoriasis, atopic eczema

Scientists from the Centre for Allergy and Environment in Munich (ZAUM), the Helmholtz Zentrum München and the Technische Universität München have reached a milestone in their specialist area with their discovery of the causes of atopic eczema and psoriasis.

22 Jul 2011

Skin dendritic cells promote distinct and opposing antigen-specific responses

A new study reveals that just as different soldiers in the field have different jobs, subsets of a type of immune cell that polices the barriers of the body can promote unique and opposite immune responses against the same type of infection.

22 Jul 2011

GIDAC recommends FDA approval of Janssen's REMICADE for treatment of pediatric UC

Janssen Biotech, Inc., formerly Centocor Ortho Biotech Inc., announced today that the Gastrointestinal Drugs Advisory Committee of the U.S. Food and Drug Administration recommended the approval of REMICADE for the treatment of moderately to severely active ulcerative colitis in pediatric patients who have had an inadequate response to conventional therapy.

22 Jul 2011

Johnson & Johnson second quarter sales increase 8.3% to $16.6 billion

Johnson & Johnson today announced sales of $16.6 billion for the second quarter of 2011, an increase of 8.3% as compared to the second quarter of 2010.

19 Jul 2011

Anti-malaria drug provides key insight into potential treatments for autoimmune diseases

In a study published recently in the journal Science Signaling Van Andel Research Institute (VARI) scientists demonstrate on the molecular level how the anti-malaria drug chloroquine represses inflammation, which may provide a blueprint for new strategies for treating inflammation and a multitude of autoimmune diseases such as arthritis, multiple sclerosis, and certain cancers.

19 Jul 2011

DARA's DB959 shows promise against type 2 diabetes

A new peroxisome proliferator activated receptor agonist currently in development, DB959, will most likely be administered orally once a day, according to a presentation made by researchers recently at the American Diabetes Association's 71st Scientific Sessions.

14 Jul 2011